SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman.

IF 2.5 4区 医学 Q2 PATHOLOGY
Pathology International Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI:10.1111/pin.13494
Megumi Nobuoka, Tatsuya Mukawa, Mai Iwaya, Shohei Shigeto, Tomonori Minagawa, Takeshi Uehara, Yoshiyuki Akiyama
{"title":"SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman.","authors":"Megumi Nobuoka, Tatsuya Mukawa, Mai Iwaya, Shohei Shigeto, Tomonori Minagawa, Takeshi Uehara, Yoshiyuki Akiyama","doi":"10.1111/pin.13494","DOIUrl":null,"url":null,"abstract":"<p><p>Renal medullary carcinoma is a rare, high-grade carcinoma arising in the renal medulla, which is usually associated with sickle cell trait, and there are very few documented cases in the Japanese population. We report a case of renal medullary carcinoma, immunohistochemically defined as SMARCB1 deficient, in a 67-year-old Japanese woman without a history of sickle cell trait. Somatic mutation of SMARCB1 and an EML4::ALK fusion gene were identified by comprehensive genomic profiling. Computed tomography revealed metastatic lesions in the retrocaval lymph nodes, liver, and bronchus. Six cycles of the dose-dense methotrexate, vinblastine, adriamycin, and cisplatin-combined chemotherapy were completed after an ultrasound-guided percutaneous biopsy of the renal tumor. After chemotherapy, the size of the original tumor in the right kidney had decreased in size, as well as the other metastatic lesions.</p>","PeriodicalId":19806,"journal":{"name":"Pathology International","volume":" ","pages":"704-707"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pin.13494","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Renal medullary carcinoma is a rare, high-grade carcinoma arising in the renal medulla, which is usually associated with sickle cell trait, and there are very few documented cases in the Japanese population. We report a case of renal medullary carcinoma, immunohistochemically defined as SMARCB1 deficient, in a 67-year-old Japanese woman without a history of sickle cell trait. Somatic mutation of SMARCB1 and an EML4::ALK fusion gene were identified by comprehensive genomic profiling. Computed tomography revealed metastatic lesions in the retrocaval lymph nodes, liver, and bronchus. Six cycles of the dose-dense methotrexate, vinblastine, adriamycin, and cisplatin-combined chemotherapy were completed after an ultrasound-guided percutaneous biopsy of the renal tumor. After chemotherapy, the size of the original tumor in the right kidney had decreased in size, as well as the other metastatic lesions.

一名日本女性患上带有 EML4::ALK 融合基因的 SMARCB1 缺失型肾髓质癌。
肾髓质癌是一种罕见的、发生在肾髓质的高级别癌症,通常与镰状细胞性状有关,在日本人群中记录的病例极少。我们报告了一例肾髓质癌病例,该病例经免疫组化鉴定为 SMARCB1 缺乏症,患者为一名 67 岁的日本女性,无镰状细胞病史。通过全面的基因组图谱分析发现了SMARCB1的体细胞突变和EML4::ALK融合基因。计算机断层扫描显示,后腔淋巴结、肝脏和支气管出现转移病灶。在超声引导下经皮活检肾脏肿瘤后,完成了六个周期的甲氨蝶呤、长春新碱、阿霉素和顺铂联合化疗。化疗后,右肾原有肿瘤的体积缩小,其他转移病灶也缩小了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathology International
Pathology International 医学-病理学
CiteScore
4.50
自引率
4.50%
发文量
102
审稿时长
12 months
期刊介绍: Pathology International is the official English journal of the Japanese Society of Pathology, publishing articles of excellence in human and experimental pathology. The Journal focuses on the morphological study of the disease process and/or mechanisms. For human pathology, morphological investigation receives priority but manuscripts describing the result of any ancillary methods (cellular, chemical, immunological and molecular biological) that complement the morphology are accepted. Manuscript on experimental pathology that approach pathologenesis or mechanisms of disease processes are expected to report on the data obtained from models using cellular, biochemical, molecular biological, animal, immunological or other methods in conjunction with morphology. Manuscripts that report data on laboratory medicine (clinical pathology) without significant morphological contribution are not accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信